AbbVie Inc. (ABBV) News and Biopharmaceutical & Healthcare Updates
AbbVie Inc., headquartered in North Chicago, Illinois, develops advanced therapies in immunology, oncology, neuroscience, eye care, and medical aesthetics. Its key products include Humira, Skyrizi, and Botox (via Allergan). AbbVie focuses on research-driven innovation and expanding patient access to next-generation treatments worldwide.
224.93
7.80
3.59 %
At close
06/04
USD
Daily range
219.86
224.94
224.94
Weekly range
208.99
224.94
224.94
European approval for Aquipta therapy lifts AbbVie stock higher
AbbVie Inc. (ABBV) stock is trading at $224.00 after rising 3.16% on the day, with the price positioned above its key short-, medium-, and long-term moving averages. ...
AbbVie stock edges higher to $217.88 after EULAR 2026 research announcement, abbvie posts
AbbVie reported that it will have 26 accepted abstracts across five rheumatic diseases at EULAR 2026.An animation showed diverse profile illustrations transitioning to on-screen text about the ...
Selling pressure pushes AbbVie stock lower in today's trading
AbbVie Inc. (ABBV) is trading at $211.98 after a $5.60 decline, down 2.57% on the day. The stock sits just above its 20-day and 50-day moving averages, but remains below the 200-day, signaling ...
ABBV stock shows mixed momentum as current volatility rises to 3.90%: weekly analysis
AbbVie Inc. (ABBV) is currently trading at $214.11, sitting slightly below both the weekly MA-20 ($215.42) and MA-50 ($214.87), but well above the MA-200 ($177.44). Over ...
AbbVie stock moves up amid positive EMA recommendations for key drugs: weekly review
AbbVie Inc. (ABBV) is currently trading at $215.70 after gaining $5.31 (2.52%) over the past week, closing in the upper part of its recent weekly range. The asset sits ...
ABBV stock holds steady below resistance at $213.82 as technical pressure persists: weekly outlook
AbbVie Inc. (ABBV) closed the week at $209.54, declining $0.85, or 0.40%, from the previous week. The price remains below both the Weekly MA-20 ($216.22) and MA-50 ...
AbbVie shares consolidate as technicals point to continued selling pressure: weekly report
AbbVie Inc. (ABBV) is currently trading at $204.68, standing below the weekly MA-20 ($217.20) and MA-50 ($213.33), while maintaining a strong buffer above the MA-200 ...
ABBV shares surge with Skyrizi and Rinvoq sales offsetting Humira decline: weekly forecast
AbbVie Inc. (ABBV) finished the week at $212.96, registering a $14.25 (6.97%) gain and closing at the top of its weekly range. The stock now trades just above its weekly ...
AbbVie stock moves down with RSI signaling oversold conditions near $204: weekly analysis
AbbVie Inc. (ABBV) is currently trading at $204.72, reflecting a weekly decline of $3.65 or 1.75%. The stock remains below its weekly MA-20 at $219.62 and MA-50 at ...
ABBV stock shows mixed momentum on neutral MACD reading: weekly review
AbbVie Inc. (ABBV) is currently trading at $208.51, reflecting a nearly flat performance over the past week — a $0.46 rise that leaves the asset essentially unchanged ...
What is behind AbbVie stock's recent drop in value today
AbbVie Inc. (ABBV) is currently trading at $203.48, down 2.20% for the day. The stock remains below its 20-day, 50-day, and 200-day moving averages ($210.89, $220.48, and $216.76, respectively), ...
AbbVie stock falls 2.05% as new ovarian cancer data shared at SGO meeting
AbbVie is sharing new data in platinum-sensitive ovarian cancer at this year’s SGO Annual Meeting.More information is available through the company’s online link.[highlights-block]Seller bias ...
AbbVie stock price forecast: sellers in control as ABBV fails to hold above support
AbbVie released a video describing key motor and non-motor symptoms of Parkinson's disease.The video also explains the terms "on time" and "off time" as they relate to Parkinson's disease ...
-2.05% for AbbVie stock as renewed selling keeps shares below key resistance
AbbVie is raising awareness about Parkinson's Disease on World Parkinson's Day.The company states that millions of people globally have Parkinson's Disease and that symptoms can significantly ...
Buying pressure lifts AbbVie stock higher in today's trading
AbbVie Inc. (ABBV) is currently priced at $211.36, rising $4.99 or 2.42% from the previous close. The stock trades below its 20-day ($213.29), 50-day ($221.11), and 200-day ($216.37) simple moving ...
AbbVie stock price forecast: Downside risk builds as ABBV drops 3.07% to $208
AbbVie Inc. (ABBV) is trading at $208.36, positioned below the SMA-20 ($216.69), SMA-50 ($221.74), and SMA-200 ($216.07), which reflects near-term and long-term downside ...
-0.83% for AbbVie stock as shares remain under key resistance levels
AbbVie says about 1 in 200 people globally live with bipolar disorder.This represents around 37 million people worldwide.[highlights-block]ABBV is trading at $209.37, which is below the MA-20 ...
-0.83% for AbbVie stock as price remains below key moving averages
AbbVie marked World Bipolar Day by emphasizing the importance of ongoing research and awareness for bipolar disorder.The company stated that millions of lives are impacted worldwide by the ...
AbbVie stock slips 0.83% as company highlights commitment to raising care standards at congress
AbbVie will present six oral presentations, two product theaters, and two IME symposiums at the 2026 congress.The company states that it has a robust portfolio and a shared commitment to patients. ...
AbbVie stock price forecast: bearish momentum persists as ABBV trades below major moving averages
AbbVie announced the presentation of 24 abstracts at AAD 2026, including one late breaker.The research covers six dermatologic conditions. These are atopic dermatitis, psoriasis, psoriatic ...
AbbVie stock edges down after AAD2026 event highlights commitment to dermatology standards
AbbVie will have a presence at #AAD2026, with presentations focused on immune-mediated skin diseases.AbbVie states the presentations underscore its commitment to raising standards of care for ...
